Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate for Acute Frequent Seizures and Status Epilepticus
NCT06352723Phase 1Not yet recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cenobamate in epilepsy and status epilepticus (SE), sponsored by Brigham and Women's Hospital. Primary endpoints: Target serum cenobamate level at 6 hours and Maintenance serum cenobamate level at 14 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cenobamate
03
Conditions
epilepsystatus epilepticus (SE)
Beyond the preview
Go deeper on NCT06352723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352723.